Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Enanta Pharmaceuticals

Request full access

Enanta Pharmaceuticals, Inc

Watertown, United StatesFounded 1998Biotech & Life Sciences

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc. operates as a clinical-stage biotechnology firm focused on the discovery and development of small molecule drugs, primarily for virology and immunology indications. Founded in 1995, the company has leveraged its chemistry-driven drug discovery platform to build a pipeline and secure a significant, long-term revenue stream. The company's headquarters are in Watertown, Massachusetts.

The company's business model is centered on a combination of in-house drug development and strategic collaborations with larger pharmaceutical companies. A cornerstone of Enanta's financial stability is its successful, long-standing collaboration with AbbVie. Through this partnership, Enanta discovered two protease inhibitors, glecaprevir and paritaprevir. Glecaprevir is a key component of MAVYRET® (MAVIRET® outside the U.S.), one of the leading curative regimens for chronic hepatitis C virus (HCV) infection, marketed by AbbVie. This collaboration provides Enanta with a steady stream of royalty revenue, which is used to fund its ongoing research and development operations. For the fiscal third quarter ending June 30, 2025, the company reported $18.3 million in revenue, consisting of these royalties. As of June 30, 2025, Enanta held $204.1 million in cash and marketable securities, which is expected to fund operations into fiscal year 2028.

Jay R. Luly, Ph.D., has served as President and CEO since July 2003, guiding the company from its venture-backed origins through a successful Initial Public Offering (IPO) on the NASDAQ (ENTA) on March 21, 2013. The IPO raised $56 million. Dr. Luly's background includes a Ph.D. in synthetic organic chemistry and extensive experience in senior drug discovery roles at Abbott Laboratories and LeukoSite, which merged with Millennium Pharmaceuticals. His journey led him to the venture capital firm Oxford Bioscience Partners as an entrepreneur in residence, through which he connected with Enanta, taking the helm at a critical turnaround point for the company.

Enanta's current R&D pipeline is focused on significant unmet needs in virology and immunology. The company's lead programs target respiratory syncytial virus (RSV) with candidates like zelicapavir (EDP-938), an N-protein inhibitor in Phase 2 trials, and EDP-323, an L-protein inhibitor. The company is also advancing its immunology pipeline, which includes a KIT inhibitor for chronic spontaneous urticaria and other mast cell-driven diseases, and a STAT6 inhibitor program targeting atopic dermatitis. Historically, Enanta has also developed clinical candidates for hepatitis B virus (HBV) and SARS-CoV-2.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2013

Enanta Pharmaceuticals in the Watertown ecosystem

Live from Dealroom

The Enanta Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Techno Venture Management
  • Oxford Bioscience Partners
  • Carlyle AlpInvest
  • Bank Vontobel AG
  • Advent International
  • Caduceus Capital Partners

Series B and later6 investors entered at this stage

  • Bioventures Investors
  • Yasuda Enterprise Development
  • Thuja Capital
  • NIBC Bank
  • Shionogi
  • Industry Ventures
Team profiled 19 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$176M

187 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Enanta Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.